being defined as in as in ref. 14. Solvent resonances were used
as internal secondary standards. NMR data for all compounds
isolated are listed in Table 1.
Experimental
General
All reactions were carried out with use of standard vacuum or
inert-atmosphere techniques as described by Shriver,10b although
some operations, such as column LC, were carried out in air. The
starting carborane 1 was prepared according to the literature.4
Fluka dichloromethane and hexane were dried over CaH2 and
freshly distilled before use. Other chemicals were of reagent or
analytical grade and were used as purchased. Column chromatog-
raphy was carried out using silica gel (Aldrich, 130–270 mesh) as
the stationary phase. The purity of individual chromatographic
fractions was checked by analytical TLC on Silufol (silica gel on
aluminium foil; detection by I2 vapour, followed by 2% aqueous
AgNO3 spray). Low-resolution mass spectra were obtained using a
Finnigan MAT Magnum ion-trap quadrupole mass spectrometer
equipped with a heated inlet option, as developed by Spectronex
AG, Basel, Switzerland (70 eV, EI ionisation). 1H and 11B, NMR
spectroscopy was performed at 9.4 T on a Varian Mercury
Synthesis of 9-CH3-5,6-R1,R2-nido-5,6-C2B8H9 (2) compounds
(where R1,R2 = H,H 2a; Me,Me 2b; Et,Et 2c, H,Ph 2d, and Ph,Ph
2e)
A solution of alkynes R1R2C2 (6 mmol, excess) and compound
1 (225 mg, 2 mmol) in hexane (20 ml) was heated in a 100 ml-
stainless steel vessel at 120 ◦C for 2 h. In the case of acetylene the
reaction was carried out by bubbling through the solution of 1 in
toluene (20 ml) for 2 h at reflux. After cooling to room temperature,
the solvents were evaporated and the desired compounds of type
2 were isolated by liquid chromatography on silica gel, using
hexane as a mobile phase. Yields, Rf values, and other properties
of compounds 2 isolated in this manner are in Table 2.
Alternative synthesis of closo anions [1-CB7H8]− (4−) and
[2-CB6H7]− (5−)
1
11
12
400 instrument. The [11B–11B]–COSY11 and H–{ B(selective)}
NMR experiments were made essentially as described earlier.13
Chemical shifts are given in ppm to high-frequency (low field)
of N = 32.083971 MHz (nominally F3B.OEt2 in CDCl3) for 11B
(quoted 0.5 ppm), N = 25.144 MHz (SiMe4) for 13C (quoted 0.5
ppm), and N = 100 MHz (SiMe4) for 1H (quoted 0.05 ppm), N
A solution of compound 1 (171 mg, 1.52 mmol) in THF (30 ml)
was treated with NaH (100 mg, 4.16 mmol) under stirring for
ca. 2 h until the hydrogen evolution ceased. The mixture was
filtered and the filtrate treated with phenylacetylene (932 mg,
9.12 mmol) and then heated at reflux for 120 h. After cooling
Table 1 NMR data
Compound
Nucleus
Chemical. shifts
1
a
5,6-C2B8H12 (2)
13C{ H}
137.5 (q, JCB = 55 Hz, C6), 69.5 (s, C5)
9-Me-5,6-C2B8H11 (2a)
11Ba,b
9.6 (s, −, B9), 6.5 (d, 149, B7), 4.5 (d, 159, B1), 1.1 (d, 155, B8), −4.6 (d, 144, B3), −11.4 (d,
152/43, B10), −31.0 (d, 177, B2), −36.4 (d, 152, B4), all [11B–11B]–COSY cross-peaks observed
6.37 (s, H6), 4.91 (s, H5), 3.50 (s, 2H,H1,7), 2.96 (s, H8), 2.87 (s, H3), 2.48 (s, H10), 0.91 (s, H4),
0.86 (s, H2), 0.67 (s, 3H,9-Me), −1.69 (s, l-H9,10), −1.99 (s, l-H8,9)
128.5 (br. s, C6), 64.7 (s, C5), −3.5 (s, 9-Me)
11
a,c
1H{ B}
1
a,c
13C{ H}
5,6-Me2-9-Me-5,6-C2B8H9 (2b)
5,6-Et2-9-Me-5,6-C2B8H9 (2c)
5-Ph-9-Me-5,6-C2B8H10 (2d)
11Ba,b
7.5 (s, −, B9), 4.4 (d, ca. 160, B1), 3.2 (d, ca. 150, B7), −0.9 (d, 150, B8), −5.0 (d, ca. 150, B3),
−6.6 (d, ca. 160/37, B10), −24.0 (d, 174, B2), −37.4 (d, 149, B4), all [11B–11B]-COSY
cross-peaks observed
11
a,c
1H{ B}
3.39 (s, H1), 3.23 (s, H7), 2.71 (s, H8), 2.63 (s, H3), 2.42 (s, H10), 2.15, 2.08 (s, 3H, 5- and
6-Me), 0.80 (s, H2), 0.70 (s, H4), 0.62 (s, 3H, 9-Me), −1.78 (s, lH8,9), −2.21 (s, lH9,10)
152.0 (br. s, C6), 84.0 (s, C5), 23.0, 21.7 (5- and 6-Me) −2.5 (s, 9-Me)
6.6 (s, −, B9), 2.2 (d, 144, B1), 1.3 (d, 131, B7), −1.2 (d, 149, B8), −6.0 (d, 144, B3), −8.5 (d,
149/27, B10), −26.6(d, 177, B2), −38.6 (d, 150, B4), all [11B–11B]-COSY cross-peaks observed
3.36 (s, H1), 3.26 (s, H7), 2.76 (s, H8), 2.62 (s, H3), 2.57 (s, H10), 2.50, 2.38 (s, 2H, 5- and 6-Et),
1.20, 1.13 (s, 3H, 5- and 6-Et), 0.81 (s, H2), 0.70 (s, H4), 0.62 (s, 3H, 9-Me), −1.90 (s, l-H9,10),
−2.22 (s, l-H8,9)
1
a
13C{ H}
11Ba,b
11
a,c
1H{ B}
1
a
13C{ H}
158.0 (br. s, C6), 89.3 (s, C5), 28.5, 28.2 (5- and 6-Et), 14.2, 13.9 (5- and 6-Et) −2.1 (s, 9-Me)
10.7 (s, −, B9), 4.6 (d, ca. 150, B7), 3,7 (d, ca. 150, B1), −0.3 (d, 146, B8), −3.2 (d, 147, B3),
−6.8 (d, 155, B10), −28.3 (d, 177, B2), −36.8 (d, 153, B4), all [11B–11B]–COSY cross-peaks
observed
11Ba,b
11
a,c
1H{ B}
7.60–7.39 (m, 5H, Ph), 6.66 (s, H6), 3.90 (s, H1), 3.59 (s, H7), 2.99 (s, 2H, H3,8), 2.67 (s, H10),
1.03 (s, 2H, H2,4), 0.71 (s, 3H, 9-Me), −1.16 (s, l-H9,10), −1.82 (s, l-H8,9)
133.6 (br. s, C6), 132.0 − 127 (m, 6C, Ph), 92.7 (s, C5), −1.8 (s, 9-Me)
32.0 (d, 168, B10), −7.3 (d, 144, B4), −9.3 (s, −, B6), −17.3 (d, 177, B3), −24.7 (d, 4B, 177,
B5,7 and 6,9), all [11B–11B]–COSY cross-peaks observed except for B6–B10
7.83 (s, 3H, Ph), 7.57 (s, 2H, Ph), 5.92 (s, H10), 3.19 (s, H2), 2.87 (s, H4), 2.51 (s, H3), 1.26,
1.21, 1.16 (s, 2H, 1H, 1H, H5,6,7, 9), 0.24 (s, 3H, 6-Me)
1
a
13C{ H}
1-Ph-6-Me-5,6-C2B8H10 (3d)
5,6-Ph2-9-Me-5,6-C2B8H9 (2e)
11Ba,b
11
a,c
1H{ B}
1
a
13C{ H}
133.5–128.8 (m, 5-Ph), 62.4 (s, C1), 54.9 (s, C2), 30.5 (s, 6-Me)
11Ba,b
8.6 (s, −, B9), 3.6 (d, 2B, ca. 150, B1,7), 0.2 (d, 133, B8), −5.0 (d, 153, B3), −6.6 (d, ca. 155,
B10), −20.3 (d, 177, B2), −36.6 (d, 152, B4), all [11B–11B]–COSY cross-peaks observed
7.58–6.82 (m, 10H, Ph), 3.71 (s, H1), 3.50 (s, H7), 2.81 (s, H10), 1.72 (s, H2), 1.04 (s, H4), 0.78
(s, 3H, 9-Me), −1.03 (s, l-H9,10), −1.61 (s, l-H8,9)
11
a,c
1H{ B}
1
a
13C{ H}
153.7 (br. s, C6), 139.6–126.9 (m, 12C, Ph), 91.6 (s, C5), −1.4 (s, 9-Me)
a In CDCl3. b d(11B) (multiplicity, 1JBH in Hz, assignment). c d(1H and 13C) (multiplicity, assignment).
This journal is
The Royal Society of Chemistry 2007
Dalton Trans., 2007, 581–584 | 583
©